US Supreme Court restores abortion pill access for now

May 14, 2026

The Supreme Court has issued a temporary order allowing mifepristone abortion pills to continue being distributed through mail services while legal challenges proceed through the courts. This decision blocks restrictions that a lower appeals court had recently imposed, which would have required the medication to be obtained through in-person visits. The ruling came after Louisiana sued the FDA, claiming that mail delivery of the abortion pill undermines the state's ban on the procedure.

Who is affected

Women seeking abortion services, particularly in states with abortion bans
Two mifepristone manufacturers who brought the case
The Food and Drug Administration (FDA)
The state of Louisiana, which filed the original lawsuit
Healthcare providers who prescribe abortion pills via telemedicine
Residents of more than 20 states that have banned or restricted abortion

What action is being taken

The Supreme Court is blocking lower court restrictions on mifepristone access through a temporary stay
Mifepristone continues to be distributed by mail and through pharmacies via telemedicine
Litigation regarding mifepristone access is playing out in the courts

Why it matters

This ruling is significant because abortion pills represent the most common method for terminating pregnancies in the United States, especially in states where surgical abortion is banned. The decision preserves access to medication abortion for women who might otherwise have limited or no options for ending pregnancies. The case also highlights the ongoing legal battles over reproductive rights following the overturning of Roe v Wade, with states attempting to enforce their abortion bans while pharmaceutical access potentially provides an alternative pathway. The outcome could affect millions of women's healthcare choices and the balance of power between state abortion restrictions and federal drug regulation authority.

What's next

The Supreme Court will decide whether to fully hear the manufacturers' case
The underlying lawsuit will continue and could be decided next year
Access to mifepristone by mail will likely remain available until that lawsuit is resolved

Read full article from source: BBC